|
|
|
The MS Society & MMJ
|
| "I believe there are 2.5 million multiple sclerosis patients who may benefit from marijuana to control spasticity."
--Dennis Petro, M.D., Neurologist |
|
| "It is the opinion of the National Multiple Sclerosis Society’s Medical Advisory Board that marijuana is not recommended as a treatment for MS. Long-term use of marijuana may be associated
with significant serious side effects. In addition, other well-tested, FDA-approved drugs are available, such as baclofen and tizanidine, to reduce spasticity in
MS". -- From The MS Information Sourcebook produced by the National MS Society. |
|
| "Collectively, these studies indicates that cannabis may substantially control the symptoms of MS, including muscle spasms, ataxia, and bladder dysfunction, and may also play a role in halting the progression of the disease."
-- GW Pharmaceuticals |
|
|
| The United States National
Multiple Sclerosis Society has steadfastly refused to provide
accurate information on the benefits of marijuana for MS patients, and
has also failed to support research. Cheryl and Jim Miller have been
engaged in a decade+ long battle with the MS Society to change this. The
cost of these failures in human terms is striking. If a newly-diagnosed
MS patient accepted the information provided by the MS Society as fact
and used it to decide not to try cannabis therapy, they could very
easily end up paralyzed and facing a premature death.
|
|
|
Read
patient testimonials to the efficacy of cannabis in treating MS symptoms |
|
|
What they are saying about
Multiple Sclerosis and Cannabis in other countries: |
| UK
MS Society
|
| National Institute for Clinical Excellence
(England & Wales): Multiple sclerosis - cannabinoids |
| GW Pharmaceuticals
on Multiple Sclerosis and cannabis. |
| 6 July 2001: GW Pharmaceuticals Press
Release: GW'S MEDICINES TARGETED AT MS, CANCER AND NEUROPATHIC PAIN - BMJ PAPER FINDINGS LIMITED TO POST-OPERATIVE PAIN |
| Alison Myrden has Multiple Sclerosis. Her condition causes her constant pain, bladder problems and leg spasms. The drugs prescribed for her condition render her comatose. Instead, Alison chooses medical marijuana.
Come spend a day with her and find out
why. |
|
|
|
STUDIES ON MULTIPLE SCLEROSIS, SPASTICITY AND OTHER
NEUROMUSCULAR DISORDERS
Clifford, David B., 1983. Tetrahydrocannabinol for tremor in Multiple Sclerosis. Ann. Neurol. 13: 669 - 671
Dunn, M. and Davis, R. 1974. The perceived effects of marijuana on spinal cord injured males. Paraplegia 12: 175.
Elkin.R., et al., 1987. Delta-9-tertrahydrocannabinol: a novel treatment of inflammatory demyelination. Fed. Proc. 46: 1378
Greenberg, H.S. et al., 1990. Marijuana and its effects on postural stability in Multiple Sclerosis patients with controls. Neurology 40(S1): 259.
Hanigan, W.C. et al., 1986. The effects of delta-9-tertrahydrocannabinol on human spasticity. J.Am.Soc.Clin.Pharmacol. 39 : 198
Lyman, W.D. et al., 1989. Delta-9-tertrahydrocannabinol: A novel treatment for experimental autoimmune encephalitis. J. Neuroimmunol 23: 73 - 82
Malec, J. et al., 1982. Cannabis effect on spasticity in spinal cord injury. Arch.Phys.Med.Rehab. 63: 116
Mauer, M. et al., 1989. Delta-9-tertrahydrocannabinol shows anti-spasticity and analgesic effects in single case double-blind trial. Eur.Sarch.Psychiatry Clin.Neorosci. 240: 1 - 4
Meinck, H.M. et al., 1989. Effect of cannabinoids on spasticity and ataxia in Multiple Sclerosis. J. Neurol. 236: 120 - 122
Petro, D. 1980. Marijuana as therapeutic agent for muscle spasm or spasticity. Psychosomatics 21: 91 - 85
Petro, D. and Ellenberger, C. Jr., 1981. Treatment of human spasticity with delta-9-tertrahydrocannabinol. J.Clin.Pharmacol. 21: 413S --416S
Truong, X.T. and Hanigan, W.C. 1986. Effect of delta-9-tertrahydrocannabinol on
electromyography measurements in human spasticity. J.Am.Soc.Clin.Pharmacol.Therap. 39: 232
Ungerleider, J.T. et al., 1987. Delta-9-tertrahydrocannabinol in the treatment of spasticity associated with Multiple Sclerosis. Adv.Alcohol Subst.Abuse 7: 39-50
|
|
